In a study reported in this issue of the *Journal*, Stahl and colleagues (pp. [1238--1248](10.1164/rccm.201807-1203OC)) provide new evidence for the safety, tolerability, and potential efficacy of inhaled 6% hypertonic saline in infants with cystic fibrosis (CF) ([@bib1]). PRESIS (Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis), a randomized, double-blinded trial, included just over 40 subjects enrolled at an average age of 3 months and followed for 1 year after being assigned to inhalation of twice daily nebulized isotonic versus hypertonic saline. No subject experienced a study-related serious adverse event or withdrew from the trial for intolerance. Studies done in children so young are often limited to safety and tolerability, but the PRESIS investigators were able to move beyond this and include measures of potential benefit to pulmonary health.

The study found that 6% hypertonic saline nebulized twice a day for 52 weeks provided a statistically significant improvement in lung function as measured by the primary efficacy outcome, lung clearance index (LCI). When compared with infants assigned to isotonic saline, those given 6% saline experienced a reduction (i.e., improvement) in LCI that was sustained over the 12-month observational period. The improvement in LCI, although not large, is similar to the difference reported between healthy children and those with CF at this age ([@bib2], [@bib3]). Larger improvements in LCI were seen in a small number of preschool-aged children after they started ivacaftor, but most of the children had higher (i.e., worse) baseline LCI values, and the few patients with normal baseline LCI tended to show little change with therapy ([@bib4]).

The feasibility and successful use of LCI in the PRESIS study is perhaps as informative as the results. This is the first publication to report the successful use of LCI in a multicenter, randomized controlled clinical trial in infants. A single-center pilot substudy within the Infant Study of Inhaled Saline trial previously demonstrated that subjects receiving inhaled 7% saline had better LCI values than those receiving isotonic saline, but the participants had a median age of \>2 years at enrollment ([@bib5]). Stahl and colleagues now extend the argument that LCI can identify the health impacts of pulmonary interventions in trials that include very young children across multiple centers. Although the clinically meaningful change in LCI at this age is uncertain, they should be commended for this work requiring repeated study-related procedures for both LCI and chest magnetic resonance imaging (MRI).

There are a number of interesting observations beyond the key findings reported in this study. The PRESIS trial was set up to take advantage of early diagnosis of CF after newborn screening, with the goal of delaying or reducing the development of CF lung disease. This demonstrates the need for sensitive measures such as LCI to detect relatively small differences in lung function when focused on very young patients who may have been diagnosed before the onset of any pulmonary symptoms. Such measures were not available in initial studies of the effect of newborn screening on CF lung disease ([@bib6]). Improvement in LCI was not associated with improvement in lung morphology as measured by MRI or the risk of predefined acute pulmonary exacerbations. Caution against overinterpreting data from a study of this size is necessary, but the findings suggest that either lung functional and structural abnormalities at this age do not align or lung imaging outcome measures may have less value in a population this young. Clearly, alternative interventions or imaging modalities may produce different results, but prior research also found a poor correlation between results from LCI and computed tomography imaging in subjects under 1 year old ([@bib7], [@bib8]). Less than one-third of children with CF appear to have bronchiectasis on computed tomography at 1 year of age ([@bib9]).

The modified Fuchs criteria were used to define acute pulmonary exacerbation in this trial. This definition is a common, valuable tool in CF clinical research ([@bib10]), but it may be less useful in such young children. One recognizes that infants, even when acutely ill, often lack many of the symptoms required by the Fuchs criteria (e.g., change in sputum, hemoptysis, dyspnea, sinus pain, chest X-ray changes, and change in lung function), which may explain why less than half of the subjects in the trial experienced a protocol-defined exacerbation over the 12-month period. Although hypertonic saline may not significantly impact the risk of acute pulmonary exacerbations in young children ([@bib11]), this also underscores the ongoing need to consider alternative quantitative efficacy measures for the youngest populations. The CF community has recently been encouraged, if not surprised, by potentially important benefits reported in studies testing CFTR (cystic fibrosis transmembrane conductance regulator) modulator drugs in infants and toddlers with CF ([@bib12]). Thus, accumulating evidence suggests that using chronic preventive therapies before the onset of observable symptoms may provide clinically meaningful benefits. More work is needed to understand long-term safety and whether or not the first year or two of life represents a window of opportunity during which any particular therapy may provide health gains that are not recoverable if treatment is delayed.

The PRESIS investigators also reported improved weight and weight-for-length with the use of 6% versus 0.9% inhaled saline. It is uncertain how this occurred, and the authors reasonably argue that such improvements may represent a systemic benefit from lessened pulmonary disease. Indeed, chronic airway or intestinal inflammation in people with CF appears to correlate inversely with nutritional status ([@bib13]--[@bib15]), and hypertonic saline may lessen the inflammatory state in older individuals ([@bib16]). Without a direct measure of airway inflammation in the present study, this remains speculative, and it is worth recognizing that four subjects (19%) who were randomized to 6% saline were pancreatic sufficient, compared with one subject in the isotonic control group. Prior larger studies of drugs that improve mucociliary clearance in older children and adults have not identified nutritional gains ([@bib11], [@bib17], [@bib18]). Ultimately, this interesting finding in infants treated with hypertonic saline will need to be replicated and better understood.

Regardless of the impact on weight, the PRESIS investigators have provided evidence of safety and tolerability, and have strengthened the rationale to pursue additional testing of chronic therapies, including hypertonic saline, in infants with CF. The need for sedation to obtain LCI measurements (or advanced imaging such as MRI) in infants will need to be carefully considered. Nonetheless, the PRESIS investigators are recognized for completing a challenging clinical trial that supports both the need for early intervention studies in young patients and the rationale to consider more than safety and tolerability in these trials. Efficacy data may not be important for regulatory approval and drug access in all countries, but they are very helpful when patients and providers wrestle with important issues such as treatment burden and cost.
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